Objectives: To evaluate the Chronic Liver Failure-Consortium Acute on Chronic Liver Failure score in acute on chronic liver failure patients admitted to ICUs from different global regions and compare discrimination ability with previously published scores. Design: Retrospective pooled analysis. Setting: Academic ICUs in Canada (Edmonton, Vancouver) and Europe (Paris, Barcelona, Chronic liver failure/Acute-on-Chronic Liver Failure in Cirrhosis [CANONIC] study). Patients: Sample of analysis of 867 cirrhotic patients with acute on chronic liver failure admitted to ICU. Cumulative incidence functions of death were estimated by acute on chronic liver failure grade at admission and at day 3. Survival discrimination abilities of Chronic Liver Failure-Consortium Acute on Chronic Liver Failure, Model for End-Stage Liver Disease, Acute Physiology and Chronic Health Evaluation II, and Child-Turcotte-Pugh scores were compared. Interventions: ICU admission for organ support. Measurements and Main Results: At admission 169 subjects (19%) had acute on chronic liver failure 1, 302 (35%) acute on chronic liver failure 2, and 396 (46%) had acute on chronic liver failure 3 with 90-mortality rates of 33%, 40%, and 74%, respectively (p < 0.001). At admission, Chronic Liver Failure-Consortium Acute on Chronic Liver Failure demonstrated superior discrimination at 90 days compared with Acute Physiology and Chronic Health Evaluation II (n = 532; concordance index 0.67 vs 0.62; p = 0.0027) and Child-Turcotte-Pugh (n = 666; 0.68 vs 0.64; p = 0.0035), but not Model for End-Stage Liver Disease (n = 845; 0.68 vs 0.67; p = 0.3). A Chronic Liver Failure-Consortium Acute on Chronic Liver Failure score greater than 70 at admission or on
A cute on chronic liver failure (ACLF) is a syndrome characterized by acute decompensation of cirrhosis, organ dysfunction, and high short-term mortality that has been recently defined in the Chronic liver failure/Acute-on-Chronic Liver Failure in Cirrhosis (CANONIC) study (1) . In this study of 1,343 patients, 30% of hospitalized decompensated cirrhotics had ACLF at study inclusion or developed it afterward with an associated 90-day mortality of 51% (1) . Derived and validated from this study, the Chronic Liver Failure-Consortium ACLF (CLIF-C ACLF) score is a clinically relevant scoring system that can be used sequentially to stratify the risk of mortality in ACLF patients (2) . It takes into account the CLIF-C Organ Failure (CLIF-C OF) (a simplified version of the original Sequential Organ Failure Assessment [SOFA] having three points by organ system) along with age and white cell count (http://www. efclif.com/scientific-activity/score-calculators/clif-c-aclf) (2) . However, only a small proportion of patients (198/1,343) in the CANONIC study were managed in the ICU setting (1) .
ACLF patients admitted to the ICU are a high-risk subset. In the United States, about 26,000 cirrhotics require ICU care for organ support with an overall cost of $3 billion dollars to the healthcare system (3, 4) . Given these significant costs, discriminating between ACLF patients with good and poor prognosis in the ICU is of importance to the healthcare provider as it may influence decisions regarding either escalating care or palliation. Currently, discussions regarding goals of care and appropriate use of palliative care are underutilized in ACLF patients (5, 6) .
The diagnostic criteria of ACLF in the original CANONIC study were based on the Chronic Liver Failure-SOFA (CLIF-SOFA) score which was modified from the original SOFA score derived for the general ICU population by Vincent et al (7) . Subsequently, the CLIF-C ACLF score was shown to outperform traditional liver-specific scores such as Model for End-Stage Liver Disease (MELD), MELD-Na, and ChildTurcotte-Pugh (CTP) (2) . Given the relative small number of ACLF patients in ICU in the original CANONIC study, the importance of evaluating the CLIF-C ACLF score in a high-risk ACLF population admitted to ICUs in Europe and North America is warranted.
In this analysis of 867 ACLF patients admitted to ICU's in Europe and North America, we examined the CLIF-C ACLF score and ACLF grade at admission and at day 3 after ICU admission and evaluated its ability to discriminate between survivors and nonsurvivors at 28 and 90 days. We also compared the performance of CLIF-C ACLF to other ICU specific (Acute Physiology and Chronic Health Evaluation [APACHE]-II) and liver-specific (MELD, CTP) scores. 
MATERIALS AND METHODS

Study Design: Patients and Setting
Data were extracted for all (n = 867) adult cirrhotic (biopsyproven cirrhosis, documented variceal hemorrhage or portal hypertension, hepatic ascites, or encephalopathy) patients meeting criteria for ACLF at admission to ICU. Inclusion criteria were 1) prior diagnosis of cirrhosis, 2) age greater than or equal to 18 years, and 3) admission to an ICU with ACLF (see below). Exclusion criteria were 1) primary diagnosis of acute (fulminant) liver failure and 2) liver transplantation prior to ICU admission.
Operational Definitions "Diagnostic criteria of ACLF grades" have been previously described elsewhere (1) . ACLF grade 1 (ACLF 1) at diagnosis was defined by presence of kidney failure (serum creatinine ≥ 2 mg/ dL) or other single organ/system failure (liver: serum bilirubin ≥ 12 mg/dL; brain: grades III-IV hepatic encephalopathy [HE] based on West Haven criteria; coagulation: international normalized ratio ≥ 2.5 or platelet count ≤ 20 × 10 9 /L; circulation: treatment with vasoconstrictors to maintain arterial pressure or inotropes to improve cardiac output; and lungs: Pao 2 /Fio 2 ≤ 200 or oxygen saturation/Fio 2 ≤ 214) if associated with renal dysfunction (serum creatinine ~ 1.5-1.9 mg/dL) and/or mild-tomoderate (grades I-II) HE. ACLF grade 2 (ACLF 2) and ACLF grade 3 (ACLF 3) were defined by the presence of 2 or ≥ 3 organ failures, respectively. The CLIF-C OF score is a simplified version of the CLIF-SOFA score based on 6 organ failures with a maximum total score of 18 and is described elsewhere (9) . The CLIF-C ACLF score is based on the CLIF-C OF score with the inclusion of age and WBC count (2) . The "APACHE II" score is described elsewhere (10) . The MELD score is currently used for organ allocation in Europe and North America (11, 12) . The "CTP" score is described elsewhere (13) .
Variables and Outcomes
Our primary exposure of interest was "severity of organ dysfunction," as defined by the CLIF-C ACLF score and ACLF grade assessment on ICU admission and at day 3 (48-72 hr post-ICU admission). Other scores evaluated in this analysis at similar time points included CLIF-C OF, MELD, CTP, and APACHE II (admission only). Coprimary outcomes were mortality at 28 and 90 days from ICU admission.
For univariate statistical comparisons among ACLF grades, the chi-square test was used for categorical variables and analyses of variance and Kruskal-Wallis test for continuous variables following testing for normality. The proportional hazards model for competing risks (PH-CR) proposed by Fine and Gray (14) was used to assess scores (CLIF-C ACLF, MELD, APACHE II, and CTP) as predictors of mortality. This model was chosen to account for liver transplantation as a "competing" event with mortality as transplant at any given time modifies the probability of death of a specific patient. Cumulative Incidence Functions (CIFs) of death were estimated by ACLF grade at admission and at day 3. Harrell's concordance index (C-index) was used to assess the discrimination ability of different scores (15, 16) . Since a PH-CR model was used, C-index values and their corresponding 95% CIs were estimated treating the transplanted patients as censored at the end of the follow-up (14, 17) . For the calculation of C-index CI's, ses were estimated by the jackknife method, based on the assumption of normality following Fieller's theorem (18) . Accordingly, C-index comparisons were performed assuming normal distributions. Significance level was set at p value of less than 0.05. Statistical analysis was performed using SAS v9.4 (SAS Institute Inc., Cary, NC).
RESULTS
Baseline Characteristics of 867 ACLF Patients in ICU
In total, 867 cirrhotic patients with ACLF (mean age [sd] 56 [11] years, 70% male) were included in this analysis ( Table 1) .
Data stratified by individual site is reported in Supplementary Table 1 (Supplemental Digital Content 1, http://links.lww.com/ CCM/D893). On ICU admission, mean APACHE II (sd) score was 22 (9) , MELD 27 (9), and CTP 11 (2) . The mean CLIF-C ACLF score at admission was 56 (10) . The most common indication for ICU admission was infection/sepsis (32%). Of 867 ACLF patients at admission, 169 (19%) had ACLF grade 1, 302 (35%) had ACLF grade 2, and 396 (46%) ACLF grade 3.
Mortality Based on ACLF Grade and CLIF Organ Failures at Admission. Mortality rates (28 and 90 d) were stratified based on ACLF grade, number of organ failures, and CLIF-C ACLF score in Table 2 . Increasing ACLF grade at admission was significantly associated with higher 28-day (ACLF 1 ~ 22%, ACLF 2 30%, ACLF 3 64%) and 90-day (ACLF 1 ~ 33%, ACLF 2 40%, ACLF 3 74%) mortality (p < 0.0001 for both). Increasing number of CLIF organ failures on ICU admission were associated with increased mortality at day 28 (one organ failure ~ 23%, five or more ~ 87%) and day 90 (one organ failure ~ 33%, five or more ~ 91%). CIF of death to 90 days accounting for death and liver transplantation stratified by ACLF grade at admission are shown in Figure 1A . Increasing ACLF grade (admission) was significantly associated with increased 90-day mortality (Gray's test p < 0.001).
Mortality Based at Admission CLIF-C ACLF Score. Mortality at 28 and 90 days post-ICU admission stratified by CLIF-C ACLF score at admission (n = 867) are shown in Table 2 . A CLIF-C ACLF score of less than 40 at admission was associated with 14% mortality at day 28 and 20% at day 90. In contrast, an admission CLIF-C ACLF score of greater than 70 was associated with 86% mortality at day 28 and 90% at day 90.
Comparison of Admission Model Performance at Day 28 and Day 90
Comparisons of discrimination abilities of CLIF-C ACLF, MELD, CTP, and APACHE II at admission are shown in Supplementary Direct comparisons between CLIF-C ACLF and other (CLIF-C OF, MELD, CTP, APACHE II) at admission in patients available for both scores (e.g., CLIF-C ACLF, and MELD) are shown in Table 3 . In comparing CLIF-C ACLF and MELD (n = 845) at admission, there were no statistically significant differences in model discrimination at day 28 was significantly associated with increased 90-day mortality (Gray's test p < 0.001).
A tabulated flow diagram of comparisons of ACLF grade at admission versus day 3 are shown graphically in Figure 2 (numerically in Supplementary Table 4 who demonstrated some improvement by day 3 had a 90-day mortality of 40% (27/67), whereas those were still ACLF grade 3 at day 3 (no change) had a corresponding 90-day mortality of 79% (88/111).
Changes in prognostic scores between admission and day 3 (delta MELD, CLIF-C ACLF, and CLIF-C OF) are shown in Supplementary Table 6 (Supplemental Digital Content 6, http://links.lww.com/CCM/D898). In 188 patients, where sufficient data were available to calculate both CLIF-C ACLF and MELD at day 3, there were no statistically significant 
DISCUSSION
Summary of Key Results
In this analysis of 867 ACLF patients admitted to ICUs in Europe and North America, increasing ACLF grade at admission and at day 3 was associated with increased mortality at 90 days (Gray's test). Patients who demonstrated clinical improvement post-ICU admission (e.g., ACLF 3 to 1 or 2) at day 3 demonstrated better outcomes at 28 and 90 days than those who did not. A CLIF-C ACLF score of greater than 70 on ICU admission was associated with 90% mortality at day 90. CLIF-C ACLF discriminated well between survivors and nonsurvivors (C-index ~ 0.75) and significantly better on direct comparison with APACHE II and CTP at similar time points (and patients), but not MELD. CLIF-C ACLF and MELD performed better at day 3 than at admission.
Comparisons With Previous Literature
Although outcomes in ACLF patients admitted to ICU are improving in general (19) (20) (21) , mortality remains high, particularly in those patients with septic shock and multiple organ failure (22) . Sepsis from bacteremia, not formally captured in prognostic scores, has been demonstrated to significantly impact outcome (23) . In our analysis, infection/sepsis was the primary reason for ICU admission in approximately one third (268/848) of ACLF patients. Furthermore, in 50% of patients at highest risk (ACLF grade 3), bacterial infection was found to be a precipitating event in their deterioration. Late identification of infection and initiation of appropriate antimicrobial therapy has been shown elsewhere to be associated with adverse outcomes not necessarily accounted for in organ failures (24, 25) .
This study builds on previous literature that demonstrates current prognostic scoring systems, including the CLIF-C ACLF score, are approximately 75% accurate (26) . Although CLIF-C ACLF takes into account extrahepatic organ failures, there are some confounders. For example, ACLF patients are often started on vasopressors for the management of acute kidney injury (AKI)/hepatorenal syndrome and it is unclear whether this truly represents cardiovascular failure or therapy for AKI. This has similarly presented challenges in other critically ill populations. For example, in the neurocritical care literature, patients will often be started on vasopressor therapy to increase mean arterial pressure as part of a neuroprotective strategy (27) . Dynamic changes in acute on chronic liver failure (ACLF) grade in patients with available data on both admission and day 3 and mortality. For each of the groups of patients defined by the ACLF grades at admission, comparisons of 28-day and 90-day mortality rates among final ACLF grades on day 3 were statistically significantly different (p < 0.0001). Similarly, for each of the groups of patients defined by the ACLF grades at day 3, comparisons of 28-day and 90-day mortality rates among original ACLF grades at admission were also statistically significantly different (p < 0.0001).
